Barrett AJ. Cathepsin D and other carboxyl proteinases. In Barrett AJ (ed): Proteinases in Mammalian Cells and Tissues. Elsevier/North Holland Biomedical Press 1977; 209–29.
Authier F, Mort JS, Bell AW et al. Proteolysis of glucagon within hepatic endosomes by membrane-associated cathepsin B and cathepsin D. J Biol Chem 1995; 270: 15798–807.PubMed
Dunn AD, Crutchfield HE, Dunn JT. Proteolytic processing of thyreoglobulin by extracts of thyroid lysosomes. Endocrinology 1991; 128(6): 3073–80.PubMed
Metaye T, Kraimpis JL, Goujon JM et al. Expression localization and thyrotropin regulation of cathepsin D in human thyroid tissues. Clin Endocrinol Metab 1997; 82 (10): 3383–8.
Ollinger K. Inhibition of cathepsin D prevents free-radical induced apoptosis in rat cardiomyocites. Arch Biochem Biophys 2000; 373 (2): 346–51.PubMed
Roberg K, Kagedal K, Ollinger K. Microinjection of cathepsin D induces caspase-dependent apoptosis in fibroblast. Am J Pathol 2002; 161 (1): 89–96.PubMed
Takuma K, Kiriu M, Mori K et al. Roles of cathepsins in riperfusion-induced apoptosis in cultured astrocytes. Neuochem Int 2003; 42 (2): 153–9.
Bidere N, Lorenzo HK, Carmona S et al. Cathepsin D triggers Bax activation, resulting in a selective apoptosis-inducing factor in T-lymphocytes entering in the early compartment phase of apoptosis. J Biol Chem 2003; 278 (33): 3140–4.
Shibata M, Kanamori S, Isahara K et al. Participation of cathepsin B and D in apoptosis of PC12 cells following serum deprivation. Biochem Biophys Res Comm 1998; 51: 199–203.
Deiss LP, Galika H, Berissi H et al. Cathepsin D protease mediates programmed cell death induced by interferon-gamma, Fas/APO-1 and TNF-alpha. EMBO J 1996; 15 (15): 3861–70.PubMed
Alfonso S, Romagnano L, Barbiaz B. Expression of cathepsin proteinases by mouse trophoblast in vivo and in vitro. Dev Dyn 1999; 216 (4-5): 374–84.
Moulton BC, Khan SA. Progestin and estrogen control of cathepsin D expression and processing in rat uterine luminal epithelium and stroma-myometrium. Proc Soc Exp Biol Med 1992; 201: 98–105.PubMed
Van der Stappen JWJ, Williams AC, Maciewcz RA, Paraskeva C. Activation of cathepsin B by a colorectal cancer cell line requires low pH and is mediated by cathepsin D. Int J Cancer 1996; 67: 547–54.PubMed
Vetvicka V, Fusek M. Activation of peripheral blood neutrophils and lymphocytes by human procathepsin D and insulin-like growth factor II. Cell Immunol 1994; 156: 332–41.PubMed
Vetvicka V, Vetvickova J, Fusek M. Participation of the propeptide on procathepsin D activation of human peripheral lymphocytes. Arch Biochem Biophys 1995; 322(1): 295–98.
Simon DI, Ezratty AM, Loscalzo J. The fibrin(ogen)olytic properties of cathepsin D. Biochemistry 1994; 33: 6555–63.PubMed
Satfig P, Hetman M, Schmahl W et al. Mice deficient for the lysosomal proteinase cathepsin D exhibit progressive atrophy of the intestinal mucosa and profound destruction of lymphoid cells. EMBO J 1995; 14 (15): 3599–3608.
Redecker B, Heckendorf B, Grosh HW et al. Molecular organization of the human cathepsin D gene. DNA Cell Biol 1991; 10: 423–31.PubMedCrossRef
Rochefort H, Liaudet-Coopman E. Cathepsin D in cancer metastasis: A protease and a ligand. APMIS 1999; 107: 86–95.PubMedCrossRef
Whitaker JN, Rhodes RH. The distribution of cathepsin D in rat tissue determined by immunocytochemistry. Am J Anat 1983; 166: 417–28.PubMed
Decker RS, Decker ML, Poole R. The distribution of lysosomal cathepsin D in cardiac myocytes. J Histochem Cytochem 1980; 28: 231–7.PubMed
Reid WA, Valler MJ, Kay J. Immunolocalization of cathepsin D in normal and neoplastic tissues. J Clin Pathol 1986; 39: 1323–30.PubMed
Robson DK, Ironside JW, Reid WA, Bougue PR. Immunolocalization of cathepsin D in the human central nervous system and central nervous system neoplasms. Neuropathol Appl Neurobiol 1990; 16: 39–44.PubMed
Parham D, Whitaker JN, Costan W, Berard CW. Cellular distribution of cathepsin D in childhood tumors. Arch Pathol Lab Med 1985; 109: 250–5.PubMed
Leto G, Gebbia N, Rausa L, Tumminello FM. Cathepsin D in the malignant progression of neoplastic diseases (Review). Anticancer Res 1992; 12: 235–40.PubMed
Rochefort H, Garcia M, Glondu M et al. Cathepsin D in breast cancer: Mechanisms and clinical applications, a 1999 overview. Clin Chim Acta 2000; 291: 157–70PubMed
Rochefort H, Chalbos D, Cunat S et al. Estrogen regulated proteases and antiproteases in ovarian and breast cancer cells. J Ster Biochem Molec Biol 2001; 76: 119–24.
Galtier-Dereure F, Capony F, Maudelonde T, Rochefort H. Estradiol stimulate cell growth and secretion of procathepsin D and a 120 kilodalton protein in human ovarian cancer cell line BG-1. J Clin Endocrinol Metab 1995; 75: 1497–502.
Touitou I, Cavailles V, Garcia M et al. Differential regulation of cathepsin D by sex steroids in mammary cancer and uterine cells. Molec Cell Endocrinol 1989; 66: 231–8.PubMed
Maudelonde T, Martinez P, Brouillet JP et al. Cathepsin D in endometrium: Induction by progesteron and potential value as tumor marker. Endocrinol Metab 1990; 70: 115–21.
Lah T, Kos J. Cysteine proteinases in cancer progression and their clinical relevance for prognosis. Biol Chem 1998; 379: 125–30.PubMed
Schmitt M, Harbeck N, Thomssen C et al. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Hemostasis 1997; 78: 285–96.
Cox G, O'Byrne KJ. Matrix Metalloproteinases and cancer. Anticancer Res 2001; 21: 4207–20.PubMed
Glondu M, Coopman P, Laurent-Matha V et al. A mutated cathepsin D devoid of its catalytic activity stimulates the growth of cancer cells. Oncogene 2001; 20(47): 6920–9.
Berchem G, Glondu M, Gleizes M et al. Cathepsin D affects multiple tumor progression steps in vivo
: Proliferation, angiogenesis and apoptosis. Oncogene 2002; 21(38): 5951–5.PubMed
Liaudet E, Derocq D, Rochefort H, Garcia M. Transfected cathepsin D stimulates high density cancer cell growth by inactivating secreted growth factors. Cell Growth Differ 1995; 66: 1045–52.
Ferrandina G, Scambia G, Bardelli F et al. Relationship betweeen cathepsin D content and disease-free survival in node-negative breast cancer patients: a meta-analysis. B J Cancer 1997; 76: 661–6.
Foekens JA, Look MP, Bolt-de Vries J et al. Cathepsin D in primary breast cancer: Prognostic evaluation involving 2810 patients. Br J Cancer 1999; 79: 300–7.PubMed
Roger S, Day CA, Fox SB. Expression of cathepsin D and estrogen receptors in male breast carcinoma. Human Pathol 1993; 24 (2): 148–51.
Mejer-vanGolder ME, Look MP, Boldt-de Vries J et al. Clinical relevance of biological factors in male breast cancer. Breast Cancer Res Treat 2001; 68 (5): 249–60.
Henzen-Logmans S, Fieret EJH, Berns EMJJ et al. Ki-67 staining in benign, borderline, malignant primary and metastatic ovarian tumors: Correlation with steroid receptors, epidermal growth factor receptor and cathepsin D. Int J Cancer 1994; 57: 468–72.PubMed
Ruppert C, Ehrenforth S, Scharrer I, Halberstadt E. Protease levels in breast ovarian and other gynecological tumor tissue. Prognostic importance in breast cancer. Cancer Detect Prev 1997; 21 (5): 452–9.PubMed
Scambia G, Panici PB, Ferrandina et al. Clinical significance of cathepsin D in primary ovarian cancer. Eur J Cancer 1994; 30A (7): 935–40.PubMed
Athanassiadou P, Sakellariou V, Petrakakou E et al. Cathepsin D immunoreactivity in ovarian cancer: Correlation with prognostic factors. Pathol Oncol Res 1998; 4 (2): 103–7.PubMed
Baekelandt M, Holm R, Trope CG et al. The significance of metastasis-related factors cathepsin D and nm23 in advanced ovarian cancer. Ann Oncol 1999; 10 (11): 1335–41.PubMed
Ferrandina G, Scambia G, Fagotti A et al. Immunoradiometric and immunohistochemical analysis of cathepsin D in ovarian cancer: Lack of association with clinical outcome. Br J Cancer 1998; 78 (12): 1645–52.PubMed
Nazeer T, Malfetano JH, Rosano TG, Ross JS. Correlation of tumor cytosol cathepsin D with differentiation and invasiveness of endometrial adenocarcinoma. Am J Clin Pathol 1992; 97 (6): 764–9.PubMed
Nazeer T, Church K, Amato C et al. Comparative quantitative immunohistochemical and immunoradiometric determinations of cathepsin D in endometrial adenocarcinoma: Predictor of tumor aggressiveness. Mod Pathol 1994; 7 (4): 469–74.PubMed
Nielsen AL, Nyholm HCJ. Endometrial adenocarcinoma of the endometrioid subtype with squamous differentiation: An immunohistochemical study of MIB-1 (ki-67 paraffin), cathepsin D and C-erbB-2 protein (p185). Int J Gynecol Pathol 1995; 14: 230–4.PubMedCrossRef
Scambia G, Benedetti Panici P, Ferrandina F et al. Significance of cathepsin D expression in uterine tumors. Eur J Cancer 1995; 31A (9): 1449–54.PubMed
Kristensen GB, Holm R, Abeler VM, Trope CG. Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor and c-erbB-2 in early cervical squamous cell carcinoma. An immunohistochemical study. Cancer 1996; 78 (3): 433–40.PubMed
Falcon O, Chirino R, Leon L et al. Low levels of cathepsin D are associated with poor prognosis in endometrial cancer. Br J Cancer 1999; 79 (3-4): 570–6.PubMed
Saygili U, Koyuncuoglu M, Altunyurt S et al. May cathepsin D immunoreactivity be used as prognostic factor in endometrial carcinoma? A comparative immunohistochemical study. Gynecol Oncol 2001; 83 (1): 20–4.PubMed
Mylonas I, Makovitzky J, Richter DU et al. Cathepsin D expression in normal, hyperplastic and malignant endometrial tissue: An immunohistochemical analysis. Acta Histochem 2003; 105 (3): 245–52.PubMed
Bazzett LS, Watkins CS, Gercel-Taylor C, Taylor DP. Modulation of proliferation and chemosensitivity by procathepsin D and its peptides in ovarian cancer. Gynecol Oncol 1999; 74: 181–87.PubMed
Salvesen GS, Dixit VM. Caspases: Intracellular signalling by proteolysis. Cell 1997; 91: 443–6.PubMed
Isahara K, Ohsawa Y, Kanamori S et al. Regulation of a novel pathway for cell death by lysosomal aspartic and cysteine proteinases. Neurosci 1999; 91 (1): 233–49.
Kohnken R, Ladror US, Wang GT et al. Cathepsin D from Alzheimer's diseased and normal brains. Exp Neurol 1995; 133: 105–12.PubMed
Cataldo AM, Barnett JL, Berman SA et al. Gene expression and cellular content of cathepsin D in Alzheimer's disease brain: Evidence for early up-regulation of the endosomal-lysosomal system. Neuron 1995; 14: 671–80.PubMed
Newbould MJ, Kelsey AM, Arango GJ et al. The choroid plexus carcinomas of childhood: histopathology, immunocytochemistry and clinicopathological correlations. Histopathology 1995; 26 (2): 137–43.PubMed
Warich M, von Bossanyi P, Dietzmann K. Expression of cathepsin D in human astrocytic neoplasias. Gen Diagn Pathol 1995; 141 (2): 193–6.
Castilla EA, Prayson RA, Abramovich CM, Cohen ML. Immunohistochemical expression of cathepsin D in meningiomas. Am J Pathol 2003; 19 (1): 123–8.
Sivaparvathi M, Sawaya R, Chintala SK et al. Expression of cathepsin D during progression of human gliomas. Neurosci Lett 1996; 208: 171–4.PubMed
Tew DS. Adhesive and invasive features in gliomas. Pathol Res Prat 2000; 196 (10): 701–11.
Castino R, Pace D, Demoz M et al. Lysosomal proteases as potential targets for the induction of apoptotic cell death in human neuroblastomas. Int J Cancer 2002; 97 (6): 775–9.PubMed
Tumminello FM, Bernacki RJ, Gebbia N, Leto G. Pepstatins, aspartic proteinase inhibitors having potential therapeutic applications. Med Res Rev 1993; 13: 199–208.PubMed
Marsigliante S, Biscozzo L, Resta L et al. Immunohistochemical and immunoradiometric evaluation of total cathepsin D in human larynx. Eur J Cancer 1994; 30B: 51–5.
Vigneswaran N, Muller S, DeRose P, Cohen C. Cathepsin D and tumor associated antigen DF3 in salivary gland neoplasia: Differential diagnostic and prognostic applications. Path Res Pract 1994; 190: 1174–84PubMed
Kos J, Smid A, Krasovec M et al. Lysosomal proteases cathepsin D, B, H and L and their inhibitors Stefin A and B in head and neck cancer. Biol Chem Hoppe-Seyler 1995; 376: 401–5.PubMed
Zeillinger H, Eder S, Schneeberger CH et al. Cathepsin D and PAI-1 expression in human head and neck cancer. Anticancer Res 1996; 16: 449–54.PubMed
Strojan P, Budhina M, Smid L et al. Cathepsin D in tissue and serum of patients with squamous cell carcinoma of the head and neck. Cancer Lett 1998; 130: 49–56.PubMed
Goussa A, Ioachim E, Peschos D et al. Immunohistochemical expression of cathepsin D in laryngeal epithelial lesions: Correlation with CD44 expression, p53 and Rb status and proliferation associated indices. Anticancer Res 1999; 19 (B): 3055–60.
Vigneswaran N, Zhao W, Dassanayake A et al. Variable expression of cathepsin B and D correlates with highly invasive and metastatic phenotype of oral cancer. Human Pathol 2000; 31 (8): 931–7.
Kawasaki G, Kato Y, Mizuno A. Cathepsin D expression in oral squamous cell carcinoma: Relationship with clinicopathologic factors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002; 93 (4): 446–54.PubMedCrossRef
Gandour-Edward ER, Trock B, Donald PJ. Predictive value of cathepsin D for cervical lymph node metastasis in head and neck squamous cell carcinoma. Head Neck 1999; 21 (8): 718–22.
Osmak M, Niksic D, Brozovic A et al. Drug resistant tumor cells have increased levels of tumor markers for invasion and metastasis. Anticancer Res 1999; 19: 3193–8.PubMed
Leto G, Tumminello FM, Gebbia N et al. Differential expression levels of urokinase-type plasminogen activator and cathepsin D in locally advanced laryngeal squamous cell carcinoma: Clinical implications. Int J Biol Markers 2001; 16 (4): 245–9.PubMed
Resnick MJM, Uhlman D, Niehans G et al. Cervical lymph node status and survival in laryngeal carcinoma: Prognostic factors. Ann Otol Rhinol Laryngol 1995; 104: 685–94.PubMed
Seiwerth S, Stambuk N, Konjevoda P et al. Immunohistochemical analysis and prognostic value of cathepsin D determination in laryngeal squamous cell carcinoma. J Chem Inf Comput Sci 2000; 40 (3): 545–9.PubMed
Lazaris AC, Lendari I, Kavantzas N et al. Correlation of tumor markers p53, bcl 2 and cathepsin D with clinicopathological features and disease free survival in laryngeal suamous cell carcinoma. Pathol Int 2000; 50: 717–24.PubMed
Maurizi M, Almadori G, Cadoni G et al. Cathepsin D concentrations in primay laryngeal cancer: Correlation with clinico-pathological parameters, EGFR status and prognosis. Int J Cancer 1996; 69 (2): 105–9.PubMed
Budihna M, Strojan P, Smid L et al. Prognostic value of cathepsin B, H, L, D and their endogenous inhibitors Stefin A and B in head and neck carcinoma. Biol Chem Hoppe-Seyler 1996; 377: 385–90.PubMed
Metaye T, Millet C, Kraimps JL et al. Estrogen receptors and cathepsin D in human thyroid tissue. Cancer 1993; 72 (6): 1991–6.PubMed
Dumont JE, Lamy F, Roger P, Maenhaut C. Physiological and pathological regulation of thyroid cell proliferation and differentiation by thyrotropin and other factors. Physiol Rev 1992; 72: 667–97.PubMed
Vassart G, Dumont JE. The thyrotropin receptor and the regulation of thyrocyte function and growth. Endocrinol Rev 1994; 13: 596–611.
Sinadinovic J, Cvejic D, Savin S et al. Enhanced acid protease activity of lysosomes from papillary thyroid carcinoma. Cancer 1989; 63: 1179–82.PubMed
Kraimps JL, Metaye T, Millett C et al. Cathepsin D in normal and neoplastic thyroid tissues. Surgery 1995; 118 (6): 1036–40.PubMed
Ruhoy SM, Clarke MR. Cathepsin B and D expression in follicular adenomas and carcinomas of the thyroid gland. Endocrin Pathol 1997; 8 (1): 49–57.
Holm R, Hoie J, Kaalhus O et al. Immunohistochemical detection of nm23/NDP kinase and cathepsin D in medullary carcinoma of the thyroid gland. Virchows Arch 1995; 427 (3): 289–94.PubMed
Ledakis P, Tester WT, Rosenberg N et al. Cathepsin D, B and L in malignant human lung tissue. Clin Cancer Res 1996; 2 (3): 561–8.PubMed
Fontanini G, Bigini D, Vignati S et al. Immunostaining of cathepsin D in non-small cell lung cancer: Correlation with morphological and biological parameters. Int J Oncol 1994; 4: 169–73.
Sloman A, Damico F, Yousem SA. Immunohistochemical markers of prolonged survival in small cell carcinoma of the lung. An immunohistochemical study. Arch Pathol Lab Med 1996; 120 (5): 465–72.PubMed
Higashiyama M, Doi O, Kodama K et al. Influence of cathepsin D expression in lung adenocarcinoma on prognosis: Possible importance of its expression in tumor cells and stromal cells and its intracellular polarization in tumor cells. J Surg Oncol 1997; 65 (1): 10–9.PubMed
Wozniack A, Drewa T, Rozwodowska M et al. Activity of some lysosomal enzymes in serum and in tumors of patients with squamous cell lung carcinoma. Neoplasma 2002; 49 (1): 10–5.
Saku T, Sakai H, Tsuda T et al. Cathepsin D and E in normal metaplastic, dysplastic and carcinomatous gastric tissue: An immunohistochemical study. Gut 1990; 31: 1250–5.PubMed
Matsuo K, Kobayashi I, Tsukuba T et al. Immunohistochemical localization of cathepsin D and E in human gastric tissue. Hum Pathol 1996; 27 (2): 184–90.PubMed
Kantsaliev AL, Kozyreva EA, Kushlinskii NE et al. Cathepsin D activity in gastric cancer. Vopr Onkol 1994; 40 (1-3): 40–6.PubMed
Kashida H, Kawamata H, Ichikawa K et al. Intracytoplasmic localization of cathepsin D reflects the invasive potential of gastric carcinoma. J Gastroenterol 2001; 36 (12): 809–15.PubMed
Allgayer H, Babic R, Grutzner KU et al. Tumor associated proteases and inhibitors in gastric cancer: Analysis of prognostic impact and individual risk protease pattern. Clin Exp Med 1998; 16(1): 62–73.
Russo A, Bazan V, Migliavacca M et al. Prognostic significance of DNA ploidy, S-phase fraction and tissue levels of aspartic, cysteine and serine proteases in operable gastric carcinoma. Clin Cancer Res 2001; 6: 178–84.
Goishi H, Tanaka S, Haruma K et al. Predictive value of cathepsin D and Ki-67 expression at the deepest penetration site for lymph node metastases in gastric cancer. Oncol Rep 2000; 7 (4): 713–8.PubMed
Ikeguchi M, Fukuda K, Oka S-I et al. Micro-lymph node metastasis and its correlation with cathepsin D expression in early gastric cancer. J Surg Oncol 2001; 77: 188–94.PubMed
Ikeguchi M, Fukuda K, Oka S et al. Clinicopathological significance of cathepsin D expression in gastric adenocarcinomas. Oncology 2001; 61: 71–8.PubMed
Garcia I, Vizoso F, Suarez C et al. Relationship of tumoral hyaluronic acid and cathepsin D contents with histological type of gastric carcinoma. Int J Biol Markers 2000; 15 (3): 215–8.PubMed
Leto G, Tumminello FM, Russo A et al. Cathepsin D activity levels in colorectal cancer: Correlation with Cathepsin B and L and other biological and clinical parameters. Int J Oncol 1995; 5: 509–515.
Adenis A, Huet G, Zerimech F et al. Cathepsin B, L and D activities in colorectal carcinomas: relationship with clinico-pathological parameters. Cancer Lett 1995; 96: 267–75.PubMed
Tumminello FM, Gebbia N, Pizzolanti G et al. Cathepsin D content in colorectal cancer. Correlation with cathepsin D activity and other biological and clinical parameters. Oncology 1995; 52: 237–42.PubMed
Theodoropoulos GE, Panoussopoulos D, Lazaris AC, Golematis BC. Evaluation of cathepsin D immunostaining in colorectal adenocarcinoma. J Surg Oncol 1997; 65 (4): 242–8.PubMed
Kanber Y, Demirbag NR, Sam AD, Aydin N. Cathepsin D expression in colorectal adenocarcinomas and adenomas. Int J Biol Markers 2002; 17 (3): 165–8.PubMed
Arao J, Fukui H, Ono Y et al. Immunohistochemical localization of cathepsin D in colorectal tumors. Dis Colon Rectum 2000; 43: 396–401.PubMed
Oh-e H, Tanaka S, Kitadai Y et al. Cathepsin D expression as possible predictor of lymph node metastasis in submucosal colorectal cancer. Eur J Cancer 2001; 37 (2): 180–8.PubMed
GalandiuK S, Miseljic S, Yang A-R et al. Expression of hormone receptors, cathepsin D and HER-2/neu
oncoprotein in normal colon and colonic disease. Arch Surg 1993; 128: 637–4.PubMed
Huet G, Zerimech F, Dieu MC et al. The state of differentiation of HT-29 colon carcinoma cells alters the secretion of cathepsin D and plasminogen activator. Int J Cancer 1994; 57: 875–82.PubMed
Stefanis D, Reffo P, Bonelli G et al. Increase in ceramide level alters the lysosomal targeting of cathepsin D prior to onset of apoptosis in HT-29 colon cancer cells. Biol Chem 2002; 383 (6): 989–99.PubMed
Movsesyan VA, Yakovlev AG, Dabaghyan CA et al. Ceramide induced neuronal apoptosis through the caspase-9/caspase-3 pathway. Biochem Biophys Res Commun 2002; 299 (2): 201–7.PubMed
Krishnamachary B, Berg-Dixon S, Kelly B et al. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res 2003; 63 (5): 1138–43.PubMed
Caruso ML, Valentini AM. Immunohistochemical p53 overexpression correlated to c-erbB and cathepsin D proteins in colorectal cancer. Anticancer Res 1996; 16: 3813–8.PubMed
Isidoro C, Demoz M, De Stefanis D et al. Altered intracellular processing and enhanced secretion of procathepsin D in a highly deviated rat hepatoma. Int J Cancer 1995; 60: 61–4PubMed
Isidoro C, Demoz M, Baccino FM, Bonelli G. High levels of proteolytic enzymes in the ascitic fluid and plasma of rats bearing Yoshida AH-130 hepatoma. Invas Metast 1995; 15: 116–24.
Maguchi S, Taniguchi N, Makita A. Elevated activity and increased mannose-6-phosphate in the carbohydrate moiety of cathepsin D from human hepatoma. Cancer Res 1988; 48: 362–7.PubMed
Kyaw A, Aung T, Htut T et al. Lysosomal enzyme activities in normals and patients with chronic liver diseases. Clin Chim Acta 1983; 151 (3): 317–23
Zuhlsdorf M, Imort M, Hasilik A, von Figura K. Molecular forms of beta hexosaminidase and cathepsin D in serum and urine of healthy subjects and patients with elevated activity of lysosomal enzymes. Biochem J 1983; 213: 733–40.PubMed
Brouillet JP, Hanslick B, Maudelonde MT et al. Increased plasma cathepsin D concentration in hepatic carcinoma and cirrhosis but not in breast cancer. Clin Biochem 1991; 24: 491–6.PubMed
Leto G, Tumminello FM, Pizzolanti G et al. Cathepsin D serum mass concentrations in patients with hepatocellular carcinoma and/or liver cirrhosis. Eur J Clin Chem Clin Biochem 1996; 34: 555–60.PubMed
Morioka M, Terayama H. Cathepsin D stimulates DNA-syntesis and mitosis in mouse liver in vivo. Exp Cell Res 1983; 151: 273–6.
Terayama H, Morioka M, Koij T. Mitogenic effects of certain cathepsins and calciferin on intact liver in vivo. Int J Biochem 1985; 17: 945–55.
Ito H, Miyazaki M, Nishimura F, Nakajima N. Secretion of extracellular matrix (fibronectin), growth factor (transforming growth factor β) and protease (cathepsin D) by hepatoma cells. Oncology 2000; 58: 261–70.PubMed
Ryvnyak VV, Gudumak VS, Onya ES. Intracellular and extracellular cathepsin D activity in the liver during cirrhosis and involution. Bull Exp Biol Med Engl Trans 1990; 109 (2): 250–3.
Terayama H, Shimizu N, Fukuzumi R. Calciferin and cathepsin D-like acid protease in serum in acute and chronic liver injuries in rats and humans. Clin Chem 1989; 35 (11): 2202–06.PubMed
Leto G, Tumminello FM, Pizzolanti G et al. Lysosomal cathepsin B and L and stefin A blood levels in patients with hepatocellular carcinoma and/or liver cirrhosis. Potential clinical implications. Oncology 1997; 54: 79–8.PubMedCrossRef
Theret N, Musso O, Turlin B et al. Increased extracellular matrix remodelling is associated with tumor progression in human hepatocellular carcinoma. Hepatol 2001; 34 (1): 82–8.
Huang XF, Wang CM, Dai XW et al. Expression of chromogranin A and cathepsin D in human primary hepatocellular carcinoma. World J Gastroenterol 2000; 6 (5): 693–8.PubMed
Yamaguchi N, Kawai K. Acid protease secreted from human pancreatic carcinoma cell line HPC-YT into serum free, chemically defined medium. Cancer Res 1986; 46: 5353–9.PubMed
Leto G, Tumminello FM, Pizzolanti G et al. Lysosomal aspartic and cysteine proteinases serum levels in pancreatic cancer or pancreatis. Pancreas 1997; 14: 22–7.PubMed
Nakata B, Appert HE, Lei SZ et al. Immunohistochemical study on cathepsin B and cathepsin D in pancreatic cancer. Oncol Rep 1994; 1 (3): 543–6.
Niedergethmann M, Hildebrand R, Wolf G et al. Angiogenesis and cathepsins expression are prognostic factors in pancreatic carcinoma after curative resection. Int J Pancreatol 2000; 28 (1): 31–9.PubMed
Conover CA, Perry JE, Tindall DJ. Endogenous cathepsin D-mediated hydrolysis of insulin-like growth factor-binding proteins in cultured human prostatic carcinoma cells. J Clin Endocrinol Metab 1995; 80: 987–93.PubMed
Nunn SE, Pechi DM, Cohen P. Acid-activated insulin-like growth factor binding protein protease activity of Cathepsin D in normal and malignant prostatic epithelial cells and seminal plasma. J Cell Physiol 1997; 171 (2): 196–204.PubMed
Mordente JA, Choudhury MS, Tazaki H et al. Hydrolysis of androgen receptor by cathepsin D: its biological significance in human prostatic cancer. Br J Urol 1998; 82 (3): 4431–5.
Vetvicka V, Vetvickova J, Fusek M. Role of procathepsin D activation peptide in prostatic cancer growth. Prostate. 2000; 44 (1): 1–7.PubMed
Vetvicka V, Vetvickova J, Hilgert I et al. Analysis of the interaction of procathepsin D activation peptide with breast cancer cells. Int J Cancer 1997; 73: 403–9.PubMed
Konno S, Cherry JP, Mordente JA et al. Role of cathepsin D in prostatic cancer cell growth and its regulation by brefeldin A. World J Urol 2001; 19 (4): 234–9.PubMed
Konno S, Mordente JA, Chen Y et al. Effects of brefeldin A on androgen receptor-mediated cellular responses in human prostatic carcinoma LNCaP cells. Mol Urol 1998; 2: 7–11.
Morikawa W, Yamamoto K, Ishikawa S et al.. Angiostatin generation by cathepsin D secreted by human prostate carcinoma cells. J Biol Chem 2000; 275 (49): 38912–20.PubMed
Cherry JP, Mordente JA, Chapman JR et al. Analysis of cathepsin D forms and their clinical implications in human prostatic cancer. J Urol 1998; 160 (6 Pt 1): 2223–8.PubMed
Yang Y, Chisholm GD, Habib FK. The distribution of PSA, cathepsin D and pS2 in BPH and cancer of the prostate. Prostate 1992; 21 (3): 201–8.PubMed
Chambon M, Rebillard X, Rochefort H et al. Cathepsin D cytosolic assay and immunohistochemical quantification in human prostate tumor. Prostate 1994; 24 (6): 320–5.PubMed
Makar R, Mason A, Kittelson JM et al. Immunohistochemical anaysis of cathepsin D in prostate carcinoma. Mod Pathol 1994; 7 (7): 747–51.PubMed
Maygarden SJ, Novotny DB, Moul JB et al. Evaluation of cathepsin D and epidermial growth factor receptor in prostatic carcinoma. Mod Pathol 1994; 7 (9): 930–6.PubMed
Ross JS, Nazeer T, Figge HL et al. Quantitative immunohistochemical determination of cathepsin D levels in prostatic carcinoma biopsies. Correlation with tumor grade, stage, PSA levels and DNA ploidy status. Am J Clin Pathol 1995; 104: 36–41.PubMed
Moul JW, Maygarden SJ, Ware JL et al. Cathepsin D and epidermal growth factor receptor immunohistochemistry does not predict recurrence of prostate cancer in patients undergoing radical prostatectomy. J Urol 1996; 155 (3): 982–5.PubMed
Theodorescu D, Broder SR, Boyd JC et al. Cathepsin D and chromogranin A as predictor of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate. Cancer 1997; 80 (11): 2109–19.PubMed
Hara I, Miyake H, Yamanaka K et al. Serum cathepsin D and its density in men with prostatic cancer as new predictor of disease progression. Oncol Rep 2002; 9 (6): 1379–83.PubMed
Myake H, Hara I, Eto H. Prediction of the extent of prostatic cancer by the combined use of systematic biopsy and serum levels of cathepsin D. Int J Urol 2003; 10 (4): 196–200.
Ioachim E, Charchanti A, Stavropoulos N et al. Expression of cathepsin D in urothelial carcinoma of the urinary bladder: An immunohistochemical study including correlation with extracellular matrix components, CD44, p53, Rb, C-erb-2 and the proliferation indices. Anticancer Res 2002; 22 (6A): 3383–8.PubMed
Dickinson AJ, Fox SB, Newcomb PV et al. An immunohistochemical and prognostic evaluation of Cathepsin D expression in 105 bladder carcinomas. J Urol 1995; 154: 237–41.PubMed
Iizumi T, Iiyama T, Tanaka W et al. Immunohistochemical studies of proliferating cell nuclear antigen and cathepsin D in transitional cell carcinoma of the urinary bladder. Urol Int 1997; 59 (2): 81–7.PubMedCrossRef
Lipponen PK. Expression of cathepsin D in transitional cell bladder tumors. J Pathol 1996; 178(1): 59–4.PubMed
Ozer E, Mungan MU, Tuna B et al. Prognostic significance and angiogenesis and immunoreactivity of cathepsin D and type IV collagen in high grade stage T1 primary bladder. Urology 1999; 54 (1): 50–5.PubMed
Salman T, el-Ahmady O, el Shafee M et al. The clinical value of cathepsin D and TNF-α in bladder cancer patients. Anticancer Res 1997; 17 (4B): 3087–90.PubMed
Carrascosa Lloret C, Cremades MA, Sanchez Sanchis M et al. Study of cathepsin D levels in invasive bladder cancer and its stroma. Correlation with tumor stage, histological grade, lymph node metastasis and survival. Actas Urol Esp 2002; 26 (5): 335–8.PubMed
Ferrier CM, van Muijen GNP, Ruiter DJ. Proteases in cutaneous melanoma. Ann Med 1998; 30: 431–42.PubMed
Fraki EJ, Hopsu-Havu VK. Proteolytic enzymes and plasminogen activator in melanoma. J Cutan Pathol 1979; 6: 195–200.PubMed
Tsushima H, Sumi H, Ikeda R et al. Purification and characterization of a cathepsin-D like enzyme from human melanoma tissue and its action on fibrinogen. Eur Rev Med Pharmacol Sci 1989; 11: 451–61.
Garcia M, Salazar-Retana G, Richer G et al. Distribution of the Mr 52,000 estrogen-regulated protein in benign breast diseases and other tissues by immunohistochemistry. Cancer Res 1986; 46: 3734–8.PubMed
Podhajcer O, Bover L, Bravo AI et al. Expression of cathepsin D in primary and metastatic human melanoma and dysplastic nevi. J Invest Dermatol 1995; 104: 340–4.PubMed
Kageshita T, Yoshii A, Kimura T et al. Biochemical and immunohistochemical analysis of cathepsins B, H, L and D in human melanocytic tumors. Arch Dermatol Res 1995; 287: 266–72.PubMed
Frohlich E, Schlagenhauff B, Mohrle M et al. Activity, expression and trascription rate of the cathepsin B, D, H and L in cutaneous melanoma. Cancer 2001; 91(5): 972–82.PubMed
Bartenjev I, Rudolf Z, Stabuc B et al. Cathepsin D expression in early cutaneous malignant melanoma. Int J Dermatol 2000; 39 (8): 599–602.PubMed
Otto FJ, Goldmann T, Biess B et al. Prognostic classification of malignant melanomas by combining clinical, histological and immunohistochemical parameters. Oncology 1999; 56 (3): 208–14.PubMed
Goldmann T, Suter L, Ribbdert D, Otto F. The expression of proteolytic enzymes at the dermal invading front of primary cutaneous melanoma predict metastasis. Pathol Res Pract 1999; 195 (3): 171–5.PubMed
Westhoff U, Fox C, Otto FJ. Quantification of cathepsin D in plasma of patients with malignant melanoma. Anticancer Res 1998; 18 (5B): 3785–8.PubMed
Kawada A, Hara K, Kominami E et al. Cathepsin B and D expression in squamous cell carcinoma. Br J Dermatol 1996; 1135: 905–10.
Goldmann T, Moorkamp A, Wiedorn KH et al. The prognostic value of the expression of collagenase IV, cathepsin D and metallothein in squamous cell carcinoma of the skin determined by immunohistochemistry. Arch Dermatol Res 2001; 293 (3): 115–20.PubMed
Leto G, Pizzolanti G, Tumminello FM and Gebbia N. Effects of E-64 (cysteine-proteinase inhibitor) and pepstatin (aspartyl-proteinase inhibitor) on metastasis formation in mice with mammary and ovarian tumors. In Vivo 1994; 8: 231–6.PubMed
Bessodes M, Antonakis K, Herscovici J. Inhibition of cathepsin D by tripeptides containing statine analogs. Biochem Pharmacol 1999; 58 (2): 329–33.PubMed
Solovyeva NI, Balayevskaya TO, Dilakian EA et al. Proteolytic enzymes at various stage of oncogenic transformation of rat fibroblasts. I Aspartyl and cysteine proteinases. Int J Cancer 1995; 60: 495–500.PubMed
Isidoro C, Demoz M, De Stefanis D et al. Synthesis, maturation and extracellular release of procathepsin D as influenced by cell proliferation or trasformation. Int J Cancer 1995; 63: 966–71.
Schwartz MK. Tissue cathepsins as tumor markers. Clin Chim Acta 1995; 237: 67–78.PubMed
Joensuu H, Toikkanen S, Isola J. Stromal cell cathepsin D expression and long-term survival in breast cancer patients. Br J Cancer 1995; 71: 155–9.PubMed
Zang Y, Beard RL, Chandraratna RA, Kang JX. Evidence of a lysosomal pathway for apoptosis induced by the synthetic retinoid CD437 in human leukaemia HL-60 cells. Cell Growth Differ 2001; 8 (5): 477–85.
Wu GS, Satfig P, Peters C, El-Deiry WS. Potential role for cathepsin D in p53-dependent tumor suppression and chemosensitivity. Oncogene 1998; 16: 2177–83.PubMed
Ikeguchi M, Sakatani T, Ueta T et al. Correlation between Cathepsin D expression and p53 protein nuclear accumulation in oesophageal squamous cell carcinoma. J Clin Pathol 2002; 55 (2): 121–6.PubMedCrossRef